2,071 results match your criteria Journal of the National Comprehensive Cancer Network JNCCN[Journal]


Efficacy of Oral Cryotherapy During Oxaliplatin Infusion in Preventing Oral Thermal Hyperalgesia: A Randomized Trial.

J Natl Compr Canc Netw 2019 Apr;17(4):358-364

aAbramson Cancer Center.

Background: Chemotherapy-induced oral thermal hyperalgesia (OTH) is a common and debilitating side effect of platinum-based anticancer agents. This study evaluated the efficacy of oral cryotherapy in preventing OTH during oxaliplatin chemotherapy infusion.

Methods: Patients with gastrointestinal cancer treated with biweekly oxaliplatin (85 mg/m2 over 120 minutes) at Abramson Cancer Center at the University of Pennsylvania were randomized to receive oral cryotherapy (ice chips) during oxaliplatin infusion or standard-of-care treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7110DOI Listing

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw 2019 Apr;17(4):367-402

27National Comprehensive Cancer Network.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0018DOI Listing
April 2019
4.178 Impact Factor

Advance Care Planning Improves Psychological Symptoms But Not Quality of Life and Preferred End-of-Life Care of Patients With Cancer.

J Natl Compr Canc Netw 2019 Apr;17(4):311-320

gCollege of Nursing, National Taipei University of Nursing and Health Science, Taipei, Taiwan.

Background: This study was conducted to examine whether a longitudinal advance care planning (ACP) intervention facilitates concordance between the preferred and received life-sustaining treatments (LSTs) of terminally ill patients with cancer and improves quality of life (QoL), anxiety symptoms, and depressive symptoms during the dying process.

Patients And Methods: Of 795 terminally ill patients with cancer from a medical center in Taiwan, 460 were recruited and randomly assigned 1:1 to the experimental and control arms. The experimental arm received an interactive ACP intervention tailored to participants' readiness to engage in this process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7106DOI Listing
April 2019
1 Read

Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma.

J Natl Compr Canc Netw 2019 Apr;17(4):322-329

aDepartment of Surgery, Division of Surgical Oncology, Department of Medicine, and.

Background: Despite an increasing burden of nonalcoholic steatohepatitis (NASH), limited data are available comparing outcomes of NASH-related hepatocellular carcinoma (HCC) versus other etiologies.

Methods: Patient demographic and tumor characteristics were collected for 1,051 patients diagnosed with NASH-, alcohol-related liver disease (ALD)-, hepatitis C virus (HCV)-, and hepatitis B virus (HBV)-related HCC at 2 large health systems from January 2008 through December 2016. Patient demographics, clinical characteristics, and survival were compared. Read More

View Article

Download full-text PDF

Source
https://jnccn.org/view/journals/jnccn/17/4/article-p322.xml
Publisher Site
http://dx.doi.org/10.6004/jnccn.2018.7105DOI Listing
April 2019
2 Reads

A Systematic Review of Clinical Decision Support Systems for Clinical Oncology Practice.

J Natl Compr Canc Netw 2019 Apr;17(4):331-338

aHealthPartners Institute, Minneapolis, Minnesota.

Background: Electronic health records are central to cancer care delivery. Electronic clinical decision support (CDS) systems can potentially improve cancer care quality and safety. However, little is known regarding the use of CDS systems in clinical oncology and their impact on patient outcomes. Read More

View Article

Download full-text PDF

Source
https://jnccn.org/view/journals/jnccn/17/4/article-p331.xml
Publisher Site
http://dx.doi.org/10.6004/jnccn.2018.7104DOI Listing
April 2019
7 Reads

Predictors of Locoregional Recurrence After Failure to Achieve Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

J Natl Compr Canc Netw 2019 Apr;17(4):348-356

aDepartment of Radiation Oncology, Washington University School of Medicine, Saint Louis, Missouri.

Background: This study evaluated factors predictive of locoregional recurrence (LRR) in women with triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy who do not experience pathologic complete response (pCR).

Methods: This is a single-institution retrospective review of women with TNBC treated with neoadjuvant chemotherapy, surgery, and radiation therapy in 2000 through 2013. LRR was estimated between patients with and without pCR using the Kaplan-Meier method. Read More

View Article

Download full-text PDF

Source
https://jnccn.org/view/journals/jnccn/17/4/article-p348.xml
Publisher Site
http://dx.doi.org/10.6004/jnccn.2018.7103DOI Listing
April 2019
6 Reads

Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.

J Natl Compr Canc Netw 2019 Apr;17(4):297-301

aDivision of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento.

Histologic transformation from adenocarcinoma to squamous cell carcinoma in lung cancer has not been reported as a mechanism of resistance to ALK inhibition. This report describes the clinical course of a female former light smoker with metastatic lung adenocarcinoma whose tumor underwent histologic transformation from a well-differentiated lung adenocarcinoma to a well-differentiated lung squamous cell carcinoma in the same location at the left mainstem bronchus while maintaining the ALK fusion oncogene without any resistance mutations. After experiencing disease progression while on crizotinib, the patient participated in clinical trials that provided early access to the novel ALK inhibitors ceritinib and alectinib before they were commercially available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.7291DOI Listing
April 2019
6 Reads

The Time Has Come!

Authors:
Margaret Tempero

J Natl Compr Canc Netw 2019 Apr;17(4):295

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0020DOI Listing

Low Provider Knowledge Is Associated With Less Evidence-Based Lung Cancer Screening.

J Natl Compr Canc Netw 2019 Apr;17(4):339-346

aGeriatric Research, Education and Clinical Center, Veterans Health Administration - Tennessee Valley Healthcare System, Nashville, Tennessee.

Background: Despite widespread recommendation and supportive policies, screening with low-dose CT (LDCT) is incompletely implemented in the US healthcare system. Low provider knowledge of the lung cancer screening (LCS) guidelines represents a potential barrier to implementation. Therefore, we tested the hypothesis that low provider knowledge of guidelines is associated with less provider-reported screening with LDCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7101DOI Listing
April 2019
1 Read

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.

J Natl Compr Canc Netw 2019 Apr;17(4):302-310

28National Comprehensive Cancer Network.

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0019DOI Listing
April 2019
1 Read

The Best Is Yet to Be.

Authors:
Wui-Jin Koh

J Natl Compr Canc Netw 2019 Mar;17(3):193

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0015DOI Listing

Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.

J Natl Compr Canc Netw 2019 Mar;17(3):245-254

aDuke Clinical Research Institute.

Background: This study examined whether associations between 21-gene recurrence score (RS) genomic testing and lower costs among patients with early-stage, estrogen receptor-positive breast cancer are observable in real-world data from the Medicare population.

Methods: A retrospective cohort study was conducted using SEER-Medicare data for a nationally representative sample of Medicare beneficiaries diagnosed from 2005 through 2011. The main outcomes were associations between RS testing and overall and chemotherapy-specific costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7097DOI Listing

Management of Immunotherapy-Related Toxicities, Version 1.2019.

J Natl Compr Canc Netw 2019 Mar;17(3):255-289

24National Comprehensive Cancer Network.

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0013DOI Listing
March 2019
32 Reads
4.178 Impact Factor

Association Between Treatment Facility Volume, Therapy Types, and Overall Survival in Patients With Stage IIIA Non-Small Cell Lung Cancer.

J Natl Compr Canc Netw 2019 Mar;17(3):229-236

dDepartment of Hematology and Oncology, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.

Background: There is significant heterogeneity in the treatment of stage IIIA non-small cell lung cancer (NSCLC). This study evaluated the therapeutic and survival disparities in patients with stage IIIA NSCLC based on the facility volume using the National Cancer Database.

Methods: Patients with stage IIIA NSCLC diagnosed from 2004 through 2015 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7086DOI Listing
March 2019
4.178 Impact Factor

Pancreatic Adenocarcinoma, Version 1.2019.

J Natl Compr Canc Netw 2019 Mar;17(3):202-210

29National Comprehensive Cancer Network.

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0014DOI Listing

Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy.

J Natl Compr Canc Netw 2019 Mar;17(3):237-243

dAdult Long-Term Follow-Up Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, and.

Background: Radiotherapy (RT) is a risk factor for nonmelanoma skin cancer (NMSC), specifically basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), but whether features, histology, or recurrence of NMSC after RT resemble those observed in the general population is unknown.

Methods: A retrospective review (1994-2017) was performed within the Adult Long-Term Follow-Up Program and Dermatology Service at Memorial Sloan Kettering Cancer Center. Demographics, clinical features, histology, treatment, and recurrence were collected for this patient cohort that was under close medical surveillance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7096DOI Listing
March 2019
1 Read

Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life.

J Natl Compr Canc Netw 2019 Mar;17(3):221-228

aMassachusetts General Hospital Cancer Center, and.

Background: Oral therapies are increasingly common in oncology care. However, data are lacking regarding the physical and psychologic symptoms patients experience, or how these factors relate to medication adherence and quality of life (QoL).

Materials And Methods: From December 2014 through August 2016, a total of 181 adult patients who were prescribed oral targeted therapy or chemotherapy enrolled in a randomized study of adherence and symptom management at Massachusetts General Hospital Cancer Center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7098DOI Listing
March 2019
3 Reads
4.178 Impact Factor

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

J Natl Compr Canc Netw 2019 Mar;17(3):194-200

eDepartment of Medicine, Division of Hematology and Medical Oncology.

Urothelial carcinoma (UC) is a common and frequently lethal cancer. Despite the presence of genomic alterations creating dependency on particular signaling pathways, the use of targeted therapies in advanced and metastatic UC has been limited. We performed an integrated analysis of whole-exome and RNA sequencing of primary and metastatic tumors in a patient with platinum-resistant UC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7264DOI Listing

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.

J Natl Compr Canc Netw 2019 Mar;17(3):211-219

bDepartment of Chronic Disease Epidemiology, Yale School of Public Health.

ABSTRACTBackground: Current guidelines recommend hydroxyurea (HU) as frontline therapy for patients with high-risk essential thrombocythemia (ET) to prevent thrombosis. However, little is known about the impact of HU on thrombosis or survival among these patients in the real-world setting.

Patients And Methods: A retrospective cohort study was conducted of older adults (aged ≥66 years) diagnosed with ET from 2007 through 2013 using the linked SEER-Medicare database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7095DOI Listing
March 2019
1 Read
4.178 Impact Factor

The NCCN Older Adult Oncology Panel Remembers Arti Hurria.

J Natl Compr Canc Netw 2019 Feb;17(2):e1-e2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0004DOI Listing
February 2019

Highlights of the NCCN Oncology Research Program.

Authors:

J Natl Compr Canc Netw 2019 Feb;17(2):xx-xxii

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0011DOI Listing
February 2019
1 Read

AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw 2019 Feb;17(2):171-189

28National Comprehensive Cancer Network.

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin's lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0008DOI Listing
February 2019
2 Reads
4.178 Impact Factor

Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.

J Natl Compr Canc Netw 2019 Feb;17(2):161-168

aCenter for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.

Pathologically positive lymph nodes (ypN+) after preoperative chemotherapy are associated with poor survival in patients with gastric cancer. Little is known about the association between response to preoperative therapy and the benefit of postoperative therapy. This retrospective cohort study of the National Cancer Database included patients with clinically node-positive (cN+) gastric cancer treated with preoperative therapy followed by surgery (2006-2014). Read More

View Article

Download full-text PDF

Source
https://jnccn.org/view/journals/jnccn/17/2/article-p161.xml
Publisher Site
http://dx.doi.org/10.6004/jnccn.2018.7093DOI Listing
February 2019
5 Reads

Impact of Incident Cancer on Short-Term Coronary Artery Disease-Related Healthcare Expenditures Among Medicare Beneficiaries.

J Natl Compr Canc Netw 2019 Feb;17(2):149-158

aDepartment of Pharmaceutical Systems and Policy, West Virginia University, and.

Healthcare spending for coronary artery disease (CAD)-related services is higher than for other chronic conditions. Diagnosis of incident cancer may impede management of CAD, thereby increasing the risk of CAD-related complications and associated healthcare expenditures. This study examined the relationship between incident cancer and CAD-related expenditures among elderly Medicare beneficiaries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472901PMC
February 2019

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.

J Natl Compr Canc Netw 2019 Feb;17(2):141-147

aWashington University School of Medicine, and.

Cyclin-dependent kinase (CDK) 4/6 inhibitors are now the standard of care for hormone receptor-positive (HR+), HER2-negative (HER-) metastatic breast cancer (MBC). However, guidelines are lacking regarding their optimal sequencing with other available agents. This study examines physician practice patterns and treatment outcomes of palbociclib and subsequent therapies in a real-world setting. Read More

View Article

Download full-text PDF

Source
http://www.jnccn.org/lookup/doi/10.6004/jnccn.2018.7094
Publisher Site
http://dx.doi.org/10.6004/jnccn.2018.7094DOI Listing
February 2019
24 Reads

Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry.

J Natl Compr Canc Netw 2019 Feb;17(2):127-139

aDepartment of Radiation Oncology, Duke University, Durham, North Carolina.

Accurate staging for small cell lung cancer (SCLC) is critical for determining appropriate therapy. The clinical impact of increasing PET adoption and stage migration is well described in non-small cell lung cancer but not in SCLC. The objective of this study was to evaluate temporal trends in PET staging and survival in the Veterans Affairs Central Cancer Registry and the impact of PET on outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7090DOI Listing
February 2019
1 Read

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

J Natl Compr Canc Netw 2019 Feb;17(2):118-126

28National Comprehensive Cancer Network.

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0009DOI Listing
February 2019
3 Reads

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

J Natl Compr Canc Netw 2019 Feb;17(2):114-117

bDepartment of Medicine, University of Chicago, Chicago, Illinois.

Uveal melanoma (UM) is an uncommon melanoma subtype with poor prognosis. Agents that have transformed the management of cutaneous melanoma have made minimal inroads in UM. We conducted a single-arm phase II study of pembrolizumab in patients with metastatic UM and performed bioinformatics analyses of publicly available datasets to characterize the activity of anti-PD-1 in this setting and to understand the mutational and immunologic profile of this disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7070DOI Listing
February 2019

Policy Strategies for the "New Normal" in Healthcare to Ensure Access to High-Quality Cancer Care.

J Natl Compr Canc Netw 2019 Feb;17(2):105-109

aNational Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania.

In recent years, oncology has seen a rapid increase in the introduction of high-cost innovative therapies while scrutiny around drug pricing has simultaneously amplified. Significant policy shifts impacting health coverage and benefit design are also being implemented, including narrow network health plans, uncertainty around the Affordable Care Act insurance exchanges, and threats to preexisting condition protections. Shifting health coverage policy combined with high drug prices and outdated reimbursement systems may create barriers to patient access to innovation and high-quality cancer care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7267DOI Listing
February 2019

: Why Won't You Believe Me?

J Natl Compr Canc Netw 2019 Feb;17(2):102-104

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7091DOI Listing
February 2019

Kids, There's an App for That!

Authors:
Margaret Tempero

J Natl Compr Canc Netw 2019 Feb;17(2):101

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0010DOI Listing
February 2019

Highlights of the NCCN Oncology Research Program.

Authors:

J Natl Compr Canc Netw 2019 Jan;17(1):xxxvii

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0005DOI Listing
January 2019

Metastatic Anal Carcinoma: The Role of Radiotherapy.

Authors:
Yi-Jen Chen

J Natl Compr Canc Netw 2019 Jan;17(1):98-100

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7112DOI Listing
January 2019

Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.

J Natl Compr Canc Netw 2019 Jan;17(1):91-97

Despite combined therapeutic approaches, there is an unmet clinical need to identify effective strategies for improved patient outcomes in treating locally advanced and metastatic cervical cancer (CC). Immunotherapy is emerging as a novel therapeutic approach in this disease for which the causative agent, human papillomavirus (HPV), has dynamic, complex immunomodulatory effects. This review explores the biologic rational of immuno-oncology in the treatment of CC and discusses the initial clinical efficacy, ongoing clinical trials, and rationale for combined multimodal treatment approaches for locally advanced and recurrent/metastatic CC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7108DOI Listing
January 2019
2 Reads

Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.

J Natl Compr Canc Netw 2019 Jan;17(1):86-90

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington.

Minimally invasive surgery (MIS) was previously considered an acceptable alternative to open radical hysterectomy in the management of early-stage cervical cancer (ESCC), but adequately powered, high-quality prospective trials evaluating survival outcomes were lacking. Recently, a large randomized phase III trial, the Laparoscopic Approach to Cervical Cancer (LACC) trial, showed that MIS for ESCC is associated with a higher risk of recurrence and death compared with open surgery. We review the LACC trial findings in depth, as well as a recent National Cancer Database analysis using propensity score weighting that supports the LACC trial findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7263DOI Listing
January 2019
2 Reads

Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw 2019 Jan;17(1):64-84

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Memorial Sloan Kettering Cancer Center; Duke Cancer Institute; University of Wisconsin Carbone Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; University of Michigan Rogel Cancer Center; Moffitt Cancer Center; Fox Chase Cancer Center; Massachusetts General Hospital Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Stanford Cancer Institute; The University of Texas MD Anderson Cancer Center; University of Colorado Cancer Center; Roswell Park Comprehensive Cancer Center; Huntsman Cancer Institute at the University of Utah; City of Hope National Medical Center; University of Alabama at Birmingham Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Mayo Clinic Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred & Pamela Buffett Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; UCSF Helen Diller Family Comprehensive Cancer Center; Patient advocate; UC San Diego Moores Cancer Center; and National Comprehensive Cancer Network.

Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical cancer are preventable through human papilloma virus (HPV) vaccination, routine screening, and treatment of precancerous lesions. However, due to inadequate screening protocols in many regions of the world, cervical cancer remains the fourth-most common cancer in women globally. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0001DOI Listing
January 2019
30 Reads

Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer.

J Natl Compr Canc Netw 2019 Jan;17(1):57-63

Exercise can ameliorate cancer- and treatment-related toxicities, but poor adherence to exercise regimens is a barrier. Exercise interventions using digital activity trackers (E-DATs) may improve exercise adherence, but data are limited for patients with cancer. We conducted a systematic review examining the feasibility of E-DATs in cancer survivors and effects on activity level, body composition, objective fitness outcomes, health-related quality of life (HRQoL), self-reported symptoms, and biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7082DOI Listing
January 2019
1 Read

Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer.

J Natl Compr Canc Netw 2019 Jan;17(1):47-56

Comparative real-world outcomes for patients with HER2-positive (HER2+) breast cancer receiving adjuvant trastuzumab outside of clinical trials are lacking. This study sought to retrospectively characterize outcomes for patients with node-negative and node-positive breast cancer receiving adjuvant trastuzumab in combination with docetaxel/cyclophosphamide (DCH), docetaxel/carboplatin/trastuzumab (TCH), or fluorouracil/epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (FEC-DH) chemotherapy in Alberta, Canada, from 2007 through 2014. Disease-free survival and overall survival (OS) analyses for node-negative cohorts receiving DCH (n=111) or TCH (n=371) and node-positive cohorts receiving FEC-DH (n=146) or TCH (n=315) were compared using chi-square, Kaplan-Meier, or Cox multivariable analysis where appropriate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7066DOI Listing
January 2019
5 Reads
4.178 Impact Factor

Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.

J Natl Compr Canc Netw 2019 Jan;17(1):39-46

Literature suggests that Oncotype DX (ODX) is cost-effective. These studies, however, tend to ignore clinical characteristics and have not incorporated population-based data regarding the distribution of ODX results across different clinical risk groups. Accordingly, this study assessed the cost-effectiveness of ODX across strata of clinical risk groups using population-based ODX data. Read More

View Article

Download full-text PDF

Source
http://www.jnccn.org/lookup/doi/10.6004/jnccn.2018.7077
Publisher Site
http://dx.doi.org/10.6004/jnccn.2018.7077DOI Listing
January 2019
10 Reads

Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer.

J Natl Compr Canc Netw 2019 Jan;17(1):29-37

Chemotherapy with or without pelvic radiotherapy (RT) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for metastatic anal cancer (MAC), despite limited clinical evidence for RT in this setting. In addition, increasing evidence shows that local therapies, including RT, may increase patient survival for some types of metastatic cancers. The purpose of this study was to evaluate the patterns of care and association between definitive pelvic RT and overall survival (OS) for patients with MAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7085DOI Listing
January 2019
5 Reads

Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.

J Natl Compr Canc Netw 2019 Jan;17(1):22-28

Bisphosphonates reduce skeletal-related events (SREs) in patients with multiple myeloma (MM) and, in some studies, improved survival. Since 2011, bisphosphonate use has been recommended by NCCN for all patients with newly diagnosed MM receiving antineoplastic therapy independent of the presence of bone disease. This study investigated their use after these guidelines were established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7079DOI Listing
January 2019
1 Read

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

J Natl Compr Canc Netw 2019 Jan;17(1):12-20

The University of Texas MD Anderson Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Fred & Pamela Buffett Cancer Center; Duke Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Mayo Clinic Cancer Center; Moffitt Cancer Center; Stanford Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; University of Wisconsin Carbone Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Fox Chase Cancer Center; UC San Diego Moores Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Michigan Rogel Cancer Center; Memorial Sloan Kettering Cancer Center; Vanderbilt-Ingram Cancer Center; Roswell Park Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; City of Hope National Medical Center; Huntsman Cancer Institute at the University of Utah; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and National Comprehensive Cancer Network.

Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation. Read More

View Article

Download full-text PDF

Source
http://www.jnccn.org/lookup/doi/10.6004/jnccn.2019.0002
Publisher Site
http://dx.doi.org/10.6004/jnccn.2019.0002DOI Listing
January 2019
23 Reads

Ovarian Clear Cell Carcinoma in Cowden Syndrome.

J Natl Compr Canc Netw 2019 01;17(1):7-11

Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Oncogénétique Clinique, CHU Montpellier, Université de Montpellier, Montpellier

Cowden syndrome (CS) is an autosomal dominant mendelian disease related to germline pathogenic variants affecting the -gene. CS is characterized by macrocephaly, mucocutaneous lesions, and an increased risk of breast and thyroid cancers. Rare ovarian cancer cases (mostly embryonic tumors) associated with have been described in the literature, but no current CS guidelines are available for ovarian cancer risk management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7065DOI Listing
January 2019
4 Reads

Value in Oncology: It Is in the Eyes of the Beholder.

J Natl Compr Canc Netw 2019 Jan;17(1):2-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7092DOI Listing
January 2019
1 Read

New Year, New Look!

Authors:
Margaret Tempero

J Natl Compr Canc Netw 2019 Jan;17(1)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0003DOI Listing
January 2019

Reviewer Page.

Authors:

J Natl Compr Canc Netw 2018 Dec;16(12):xxxi

View Article

Download full-text PDF

Source
December 2018

Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?

J Natl Compr Canc Netw 2018 Dec;16(12):1547-1548

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7107DOI Listing
December 2018